BSX
Boston Scientific Corporation · Healthcare · Medical - Devices
Señales de momentum (gestores comparables):
amplitud de titulares +9.5% ·
flujo de acciones +2.4% ·
nuevas posiciones netas +8.7%
· fórmula
Acumulación amplia: acciones en aumento entre más titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 7.31M | $317.13M | n/a | n/a |
| Q2 2026 | 180 | -1 | 1.05B | $45.33B | +3 | −5 |
| Q1 2026 | 185 | -2 | 1.08B | $67.75B | +2 | −5 |
| Q4 2025 | 186 | +1 | 1.13B | $107.60B | +2 | n/a |
| Q3 2025 | 28 | 0 | 719.46M | $70.18B | n/a | −1 |
| Q2 2025 | 26 | -1 | 668.30M | $71.71B | n/a | −1 |
| Q1 2025 | 24 | +1 | 275.71M | $27.75B | +1 | n/a |
| Q4 2024 | 23 | -1 | 268.54M | $23.93B | n/a | −1 |
| Q3 2024 | 23 | +2 | 200.54M | $16.75B | +2 | n/a |
| Q2 2024 | 21 | n/a | 195.84M | $15.04B | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 37.83M | -0.3% | $3.17B | 2.3% | ▼ Trim | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 32.82M | +2.2% | $2.75B | 0.5% | ▲ Add | 2 | SEC ↗ ×9 |
| 3 | Geode Capital Management ✦ (pasivo) | 29.58M | +1.6% | $2.47B | 0.2% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Capital World Investors ✦ | 21.68M | +6.3% | $1.82B | 0.3% | ▲ Add | 2 | SEC ↗ |
| 5 | Norges Bank ✦ (pasivo) | 19.09M | +6.8% | $1.60B | 0.2% | ▲ Add | 2 | SEC ↗ |
| 6 | Millennium Management ✦ | 11.36M | +0.8% | $910.05M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 9.79M | -21.6% | $820.66M | 0.9% | ▼ Trim | 2 | SEC ↗ ×2 |
| 8 | T. Rowe Price ✦ | 8.25M | +2.2% | $691.47M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 9 | Marshall Wace ✦ | 8.24M | +22.6% | $690.56M | 0.9% | ▲ Add | 2 | SEC ↗ ×3 |
| 10 | Arrowstreet Capital ✦ | 5.11M | +6.0% | $427.80M | 0.4% | ▲ Add | 2 | SEC ↗ |
| 11 | Fisher Asset Management ✦ | 4.77M | +17.0% | $399.89M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 12 | Point72 Asset Management ✦ | 3.38M | +8.2% | $283.40M | 1.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Adage Capital Partners ✦ | 2.60M | -7.3% | $218.18M | 0.4% | ▼ Trim | 2 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 1.76M | +114.5% | $147.16M | 0.2% | ▲ Add | 2 | SEC ↗ ×2 |
| 15 | Two Sigma Investments ✦ | 1.15M | -37.8% | $96.63M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 16 | Viking Global Investors ✦ | 967.21K | Nuevo | $81.05M | 0.3% | New | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 964.95K | +37.4% | $80.35M | 0.1% | ▲ Add | 2 | SEC ↗ ×4 |
| 18 | Bridgewater Associates ✦ | 356.76K | -69.6% | $29.90M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 19 | Soros Fund Management ✦ | 350.00K | +40.0% | $29.33M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 20 | Renaissance Technologies ✦ | 258.02K | Nuevo | $21.62M | 0.0% | New | 1 | SEC ↗ |
| 21 | GAMCO Investors ✦ | 120.29K | +16.4% | $10.08M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 22 | Dodge & Cox ✦ | 95.30K | -1.9% | $7.99M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 23 | Gotham Asset Management ✦ | 7.96K | +30.1% | $666,629 | 0.0% | ▲ Add | 2 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Viking Global Investors | $81.05M | 0.3% |
| Renaissance Technologies | $21.62M | 0.0% |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 1,653 tenedores, 1.31B acciones, $78.98B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Director · 2.04K acc. @ 49.22 · $100,408
Ventas en mercado abierto (S)
Sin ventas en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología